I-Gel in Out-of-hospital Cardiac Arrest in Norway | NCT02090218 | Trialant

I-Gel in Out-of-hospital Cardiac Arrest in Norway | NCT02090218 | Trialant

Sponsor/Collaborators Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
I-Gel	Active Comparator	I-Gel supraglottic airway device	Device: I-Gel
LTS, ETI or other airway practice	Active Comparator	Laryngeal tube, endotracheal tube or other current airway management practice	Device: LTS, ETI or current airway management practice

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
ventilation success	ventilation success defined as successful insertion of device with visible chest movement with each ventilation, audible air passage on auscultation, and ETCO2 confirmation (if available) of tube placement	up to 24 hours

Secondary Outcomes

Measure	Description	Time Frame
survival to hospital discharge / 30-day survival		up to 30 days
levels of ETCO2 related to the presence and quality of bystander CPR		up to 24 hours
cerebral function assessed by Glascow Outcome Score at discharge from hospital

Contacts/Locations Module

Overall Officials

Name	Affiliation	Role
Geir A Sunde, MD	Haukeland University Hospital	Principal Investigator
Jon-Kenneth Heltne, MD, PhD	Haukeland University Hospital	Study Chair
Guttorm Brattebø, MD	Haukeland University Hospital	Study Chair
Hanne Klausen, MD	Haukeland University Hospital	Study Director

Condition Browse Module